Original articlePatterns of antimicrobial resistance in lesions of hidradenitis suppurativa
Section snippets
Study population
After institutional review board approval, we conducted a cross-sectional analysis of 632 patients with a dermatologist diagnosis of HS who were seen at the Johns Hopkins Medical Institutions from 2010 to 2015. We included 239 patients who had bacterial culture data from HS lesions, all of which were sampled using swabs.
Definition of variables
Using information from electronic medical records, the first recorded bacterial culture for each patient was examined to collect data on the isolated bacterial species and the
Results
Of the patients with information on antibiotic use at the time of bacterial culture (N = 227), 122 (54%) had documented antibiotic use (Table I). Individuals receiving antibiotics showed similar characteristics according age, gender, ethnicity, and body mass index compared with individuals not receiving antibiotics at the time of bacterial culture (P > .05 for all). The most common antibiotics used were tetracyclines (26%), topical clindamycin (19%), oral clindamycin (9%), and
Discussion
Although HS is not primarily an infectious disease, antibiotics are often the first-line treatment for HS, used for their anti-inflammatory, antimicrobial, and immunomodulatory properties.5, 6 However, the efficacy of certain antibiotics in HS may be suboptimal,3 and the associations observed in this study suggest that these antibiotics may be inducing antibiotic resistance in patients with HS. More specifically, we observed antimicrobial resistance in isolates of Staphylococcus aureus, which
References (8)
- et al.
Bacteriology of hidradenitis suppurativa/acne inversa: a review
J Am Acad Dermatol
(2015) Clinical practice. Hidradenitis suppurativa
N Engl J Med
(2012)- et al.
Bacteriology of hidradenitis suppurativa - which antibiotics are the treatment of choice?
Acta Derm Venereol
(2014) - et al.
The bacteriology of hidradenitis suppurativa: a systematic review
Exp Dermatol
(2015)
Cited by (65)
Taiwanese Dermatological Association (TDA) consensus recommendations for the definition, classification, diagnosis, and management of hidradenitis suppurativa
2024, Journal of the Formosan Medical AssociationHydroxychloroquine for the treatment of hidradenitis suppurativa
2023, JAAD Case ReportsReply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”
2023, Journal of the American Academy of DermatologyCytochrome P450 Genes Mediated by DNA Methylation Are Involved in the Resistance to Hidradenitis Suppurativa
2023, Journal of Investigative DermatologyAntibiotic resistance in dermatology: The scope of the problem and strategies to address it
2022, Journal of the American Academy of DermatologyCitation Excerpt :Daily administration of parenteral ertapenem is a safe and effective alternative for refractory disease.44 A 2010-2015 cross-sectional analysis of HS patients demonstrated a significantly higher prevalence of clindamycin-resistant S aureus in patients using topical clindamycin compared to patients using no antibiotics.45 Moreover, a 2019 study by Bettoli et al46 found that 84.7% of bacterial cultures from HS patients harbored resistance against tetracyclines.
Microbiota Perturbations in Hidradenitis Suppurativa
2022, A Comprehensive Guide to Hidradenitis Suppurativa
Funding sources: None.
Conflicts of interest: None declared.